Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM185PE | TNBC | Luminal | Everolimus | MTOR | MTOR | 0.000853 | uM | 12269.164 | 1.3320 | 3.0655 | 0.4042 | |
| SUM185PE | TNBC | Luminal | Everolimus | MTOR | MTOR | 0.00427 | uM | 12269.164 | 1.3535 | 3.2294 | 0.4042 | |
| SUM185PE | TNBC | Luminal | Everolimus | MTOR | MTOR | 0.0213 | uM | 12269.164 | 0.9861 | 0.9321 | 0.4042 | |
| SUM185PE | TNBC | Luminal | Everolimus | MTOR | MTOR | 0.107 | uM | 12269.164 | 0.7456 | -0.0328 | 0.4042 | |
| SUM185PE | TNBC | Luminal | Everolimus | MTOR | MTOR | 0.533 | uM | 12269.164 | 1.0553 | 1.2851 | 0.4042 | |
| SUM185PE | TNBC | Luminal | Everolimus | MTOR | MTOR | 2.67 | uM | 12269.164 | 0.9430 | 0.7298 | 0.4042 | |
| SUM185PE | TNBC | Luminal | Everolimus | MTOR | MTOR | 13.3 | uM | 12269.164 | 0.6495 | -0.3124 | 0.4042 | |
| SUM185PE | TNBC | Luminal | Everolimus | MTOR | MTOR | 66.7 | uM | 12269.164 | 0.4659 | -0.6978 | 0.4042 | |
| SUM225CWN | HER2amp | Basal A | Everolimus | MTOR | MTOR | 0.000171 | uM | 12098.164 | 0.9089 | 0.8570 | 1.2878 | |
| SUM225CWN | HER2amp | Basal A | Everolimus | MTOR | MTOR | 0.000853 | uM | 12098.164 | 0.9056 | 0.8518 | 1.2878 | |
| SUM225CWN | HER2amp | Basal A | Everolimus | MTOR | MTOR | 0.00427 | uM | 12098.164 | 0.7771 | 0.6443 | 1.2878 | |
| SUM225CWN | HER2amp | Basal A | Everolimus | MTOR | MTOR | 0.0213 | uM | 12098.164 | 0.6824 | 0.4864 | 1.2878 | |
| SUM225CWN | HER2amp | Basal A | Everolimus | MTOR | MTOR | 0.107 | uM | 12098.164 | 0.4873 | 0.1444 | 1.2878 | |
| SUM225CWN | HER2amp | Basal A | Everolimus | MTOR | MTOR | 0.533 | uM | 12098.164 | 0.5553 | 0.2666 | 1.2878 | |
| SUM225CWN | HER2amp | Basal A | Everolimus | MTOR | MTOR | 2.67 | uM | 12098.164 | 0.5010 | 0.1694 | 1.2878 | |
| SUM225CWN | HER2amp | Basal A | Everolimus | MTOR | MTOR | 13.3 | uM | 12098.164 | 0.4361 | 0.0498 | 1.2878 | |
| SUM225CWN | HER2amp | Basal A | Everolimus | MTOR | MTOR | 66.7 | uM | 12098.164 | 0.0070 | -0.9574 | 1.2878 | |
| SUM229PE | TNBC | - | Everolimus | MTOR | MTOR | 0.000171 | uM | 11058.156 | 0.9465 | 0.9455 | 1.9927 | |
| SUM229PE | TNBC | - | Everolimus | MTOR | MTOR | 0.000853 | uM | 11058.156 | 1.0032 | 1.0032 | 1.9927 | |
| SUM229PE | TNBC | - | Everolimus | MTOR | MTOR | 0.00427 | uM | 11058.156 | 1.0099 | 1.0099 | 1.9927 | |
| SUM229PE | TNBC | - | Everolimus | MTOR | MTOR | 0.0213 | uM | 11058.156 | 0.9146 | 0.9124 | 1.9927 | |
| SUM229PE | TNBC | - | Everolimus | MTOR | MTOR | 0.107 | uM | 11058.156 | 0.8174 | 0.8076 | 1.9927 | |
| SUM229PE | TNBC | - | Everolimus | MTOR | MTOR | 0.533 | uM | 11058.156 | 0.8300 | 0.8215 | 1.9927 | |
| SUM229PE | TNBC | - | Everolimus | MTOR | MTOR | 2.67 | uM | 11058.156 | 0.8179 | 0.8081 | 1.9927 | |
| SUM229PE | TNBC | - | Everolimus | MTOR | MTOR | 13.3 | uM | 11058.156 | 0.7408 | 0.7204 | 1.9927 |